Skip to main content
TipRanks
Go Ultimate75% OFF

EyePoint Pharmaceuticals (PV3B) Ratios

1 Followers

EyePoint Pharmaceuticals Ratios

DE:PV3B's free cash flow for Q3 2026 was $-88.02M. For the 2026 fiscal year, DE:PV3B's free cash flow was decreased by $-1.21M and operating cash flow was $-86.82M. See a summary of the company’s cash flow.

Financial ratios
RatiosDec 25Dec 24Dec 23Dec 22Dec 21
Liquidity Ratios
Current Ratio8.887.815.455.0010.05
Quick Ratio8.837.775.394.929.90
Cash Ratio2.752.034.452.777.55
Solvency Ratio-3.97-1.58-0.79-1.19-0.70
Operating Cash Flow Ratio-6.49-2.570.03-1.88-2.12
Short-Term Operating Cash Flow Coverage0.000.000.00-6.210.00
Net Current Asset Value$ 270.77M$ 301.34M$ 255.94M$ 88.82M$ 158.75M
Leverage Ratios
Debt-to-Assets Ratio0.060.050.010.260.15
Debt-to-Equity Ratio0.070.060.020.480.21
Debt-to-Capital Ratio0.070.060.020.320.18
Long-Term Debt-to-Capital Ratio0.000.000.000.230.17
Financial Leverage Ratio1.191.241.331.871.43
Debt Service Coverage Ratio0.00-9236.86-55.40-7.07-9.12
Interest Coverage Ratio0.00-10418.14-60.20-31.24-10.05
Debt to Market Cap0.000.000.000.300.10
Interest Debt Per Share0.310.390.161.331.55
Net Debt to EBITDA0.340.604.010.512.78
Profitability Margins
Gross Profit Margin93.41%91.42%89.93%79.89%77.86%
EBIT Margin-738.42%-302.19%-150.95%-239.26%-143.26%
EBITDA Margin-731.06%-298.63%-149.94%-233.36%-135.76%
Operating Profit Margin-775.98%-337.06%-163.13%-240.65%-149.64%
Pretax Profit Margin-738.53%-302.22%-153.66%-246.97%-158.14%
Net Profit Margin-739.42%-302.43%-153.84%-246.97%-158.14%
Continuous Operations Profit Margin-739.42%-302.43%-153.84%-246.97%-158.14%
Net Income Per EBT100.12%100.07%100.12%100.00%100.00%
EBT Per EBIT95.17%89.67%94.20%102.63%105.68%
Return on Assets (ROA)-63.73%-31.27%-19.93%-56.70%-22.18%
Return on Equity (ROE)-75.78%-38.89%-26.58%-106.11%-31.68%
Return on Capital Employed (ROCE)-74.45%-39.48%-25.71%-68.33%-23.06%
Return on Invested Capital (ROIC)-73.99%-39.48%-25.71%-63.51%-22.98%
Return on Tangible Assets-63.73%-31.27%-19.93%-56.70%-24.28%
Earnings Yield-17.33%-31.20%-8.08%-78.29%-16.60%
Efficiency Ratios
Receivables Turnover48.1971.2957.172.672.01
Payables Turnover0.200.320.711.411.11
Inventory Turnover1.141.611.192.882.26
Fixed Asset Turnover1.551.484.505.6013.54
Asset Turnover0.090.100.130.230.14
Working Capital Turnover Ratio0.100.140.220.240.28
Cash Conversion Cycle-1525.39-920.75-198.343.7113.12
Days of Sales Outstanding7.575.126.39136.67181.36
Days of Inventory Outstanding320.30226.65307.79126.52161.41
Days of Payables Outstanding1853.271152.52512.51259.48329.65
Operating Cycle327.88231.77314.18263.19342.77
Cash Flow Ratios
Operating Cash Flow Per Share-3.28-2.240.05-1.74-1.74
Free Cash Flow Per Share-3.32-2.31-0.04-1.80-1.75
Dividend Paid and CapEx Coverage Ratio-73.20-31.150.54-30.23-321.13
Capital Expenditure Coverage Ratio-73.20-31.150.54-30.23-321.13
Operating Cash Flow Coverage Ratio-10.53-5.770.38-1.40-1.28
Operating Cash Flow to Sales Ratio-7.65-2.920.04-1.57-1.36
Free Cash Flow Yield-18.19%-31.06%-0.18%-51.42%-14.28%
Valuation Ratios
Price-to-Earnings (P/E) Ratio-5.76-3.21-12.38-1.28-6.03
Price-to-Sales (P/S) Ratio42.669.6919.043.159.53
Price-to-Book (P/B) Ratio4.371.253.291.361.91
Price-to-Free Cash Flow (P/FCF) Ratio-5.50-3.22-544.85-1.94-7.00
Price-to-Operating Cash Flow Ratio-5.57-3.32467.26-2.01-7.03
Price-to-Earnings Growth (PEG) Ratio-0.16-0.120.37-0.040.14
Enterprise Value Multiple-5.49-2.64-8.69-0.84-4.24
Enterprise Value1.26B341.57M599.76M81.32M212.61M
EV to EBITDA-5.49-2.64-8.69-0.84-4.24
EV to Sales40.147.8913.031.965.76
EV to Free Cash Flow-5.17-2.62-372.99-1.21-4.23
EV to Operating Cash Flow-5.24-2.71319.87-1.25-4.24
Tangible Book Value Per Share4.185.986.852.585.62
Shareholders’ Equity Per Share4.185.986.852.586.41
Tax and Other Ratios
Effective Tax Rate-0.00-0.00-0.000.000.00
Revenue Per Share0.430.771.181.111.28
Net Income Per Share-3.17-2.32-1.82-2.74-2.03
Tax Burden1.001.001.001.001.00
Interest Burden1.001.001.021.031.10
Research & Development to Revenue7.053.071.411.200.77
SG&A to Revenue1.651.210.870.840.69
Stock-Based Compensation to Revenue0.890.850.260.340.20
Income Quality1.040.96-0.030.640.86

Currency in USD